OPL 21.4% 1.7¢ opyl limited

Opyl links with PAR/Paradigm Pharmaceuticals

  1. 1,182 Posts.
    lightbulb Created with Sketch. 589
    Opyl is providing consulting services to Paul Rennie's Paradigm Pharmaceuticals.

    OPL chairman, Saurabh Jain, discloses the PAR relationship in an 8 minute interview with Niv Gagan, CEO of Peak Asset Management.

    Dagan is OPL's second largest shareholder.

    He notes in the interview posted on LinkedIn that he'll be joining OPL directors for dinner.

    Paradigm is planning an important Phase 3 clinical trial of it's key iPPS compound in osteo-arthritis.

    It seems likely that OPL's AI tech will be used in PAR's trial design.
 
watchlist Created with Sketch. Add OPL (ASX) to my watchlist
(20min delay)
Last
1.7¢
Change
0.003(21.4%)
Mkt cap ! $2.902M
Open High Low Value Volume
1.7¢ 1.7¢ 1.7¢ $2.784K 163.7K

Buyers (Bids)

No. Vol. Price($)
2 34500 1.7¢
 

Sellers (Offers)

Price($) Vol. No.
2.3¢ 4000 1
View Market Depth
Last trade - 13.29pm 17/09/2024 (20 minute delay) ?
OPL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.